Pasireotide: complete guide

Pasireotide is a cyclic peptide somatostatin analog first approved by FDA as Signifor in 2012. This guide covers its structure, mechanism, labeled uses, trials and warnings.

Complete guide5 min read

Key takeaway

FDA first approved pasireotide as Signifor on December 14, 2012, for Cushing’s disease. Signifor LAR followed on December 15, 2014, for acromegaly. In a head-to-head acromegaly trial, 31.3% reached the primary control target with pasireotide versus 19.2% with octreotide. Hyperglycemia is a leading side effect.

At a glance

Article typeComplete guide
Regulatory statusFDA-approved“Drugs@FDA lists the original approval of Signifor on December 14, 2012.” (this article)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited2 in this article · 2 across 1 article on Pasireotide
Related productsIncretin analogs

Pasireotide is a cyclic peptide that mimics somatostatin, the body’s brake on several pituitary hormones. In lab binding tests, it binds somatostatin receptor type 5 most tightly. This guide covers its structure, mechanism, FDA-labeled uses, pivotal trials and label warnings. Sources were checked on November 17, 2026.

Quick answer: Pasireotide is a prescription somatostatin analog sold as Signifor and Signifor LAR by Recordati Rare Diseases. Its labels cover Cushing’s disease when pituitary surgery is not an option or has not worked, and acromegaly after inadequate response to surgery. It lowers ACTH and GH secretion. There is no boxed warning, but high blood sugar is common.

Vitrapep does not sell pasireotide; this page is a reference summary of published research and regulatory information.

What is pasireotide?

The Signifor label describes pasireotide as “a cyclohexapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin” (Signifor label, 2024). A cyclohexapeptide is a ring of six amino acids. ChEBI text in PubChem calls it a “six-membered homodetic cyclic peptide.” Its listed building blocks include L-phenylglycine, D-tryptophan and L-lysine.

That ring of amino acids is why it counts as a peptide. PubChem lists the formula as C58H66N10O9 and the molecular weight as 1,047.2 g/mol (PubChem CID 9941444). Signifor contains the diaspartate salt, which the label gives as 1,313.41 g/mol. Signifor LAR contains the pamoate salt. For background, see our guide to types of peptides.

Drugs@FDA lists the original approval of Signifor (NDA 200677) on December 14, 2012 (Drugs@FDA, Signifor). Signifor LAR (NDA 203255) was approved on December 15, 2014 (Drugs@FDA, Signifor LAR). Both records now list Recordati Rare as the company.

Table 1

Pasireotide: key facts

Fact Detail
Structure type Cyclic hexapeptide (six-membered homodetic ring)
Class Somatostatin analog
Molecular formula C58H66N10O9
Molecular weight 1,047.2 g/mol (PubChem); diaspartate salt 1,313.41 g/mol (Signifor label)
First FDA approval December 14, 2012 (Signifor, NDA 200677)
Brand names (US) Signifor, Signifor LAR

How does pasireotide work?

Somatostatin is a natural hormone that holds back the release of other hormones. Pasireotide copies that effect. The Signifor label states: “Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTRs).” There are five SSTR subtypes. In lab binding tests reported in the label, pasireotide bound subtype 5 most tightly. It also bound subtypes 2, 3 and 1, with little binding to subtype 4.

ACTH is the pituitary hormone that drives cortisol, and Cushing’s disease involves too much of it. The label says pasireotide activates SSTRs, “resulting in inhibition of ACTH secretion,” which lowers cortisol. For acromegaly, the Signifor LAR label says SSTR2 and SSTR5 binding “may be relevant for inhibition of GH secretion” (Signifor LAR label, 2024). Other somatostatin analogs include octreotide and lanreotide.

What is pasireotide approved for?

The two products have different labels:

  • Signifor: adults with Cushing’s disease “for whom pituitary surgery is not an option or has not been curative.”
  • Signifor LAR, acromegaly: patients “who have had an inadequate response to surgery” and/or for whom surgery is not an option.
  • Signifor LAR, Cushing’s disease: patients for whom pituitary surgery is not an option or has not been curative.

Drugs@FDA lists a Signifor LAR supplement classed as a new indication, approved on June 29, 2018.

What did the key trials show?

Cushing’s disease. A phase 3 human trial randomized 162 adults with Cushing’s disease to two pasireotide treatment arms. The primary end point was normal urinary free cortisol at month 6 without a treatment increase. It was met by 12 of 82 patients (14.6%) in one arm and 21 of 80 (26.3%) in the other. Hyperglycemia-related adverse events occurred in 118 of the 162 patients (Colao et al., 2012). The registry record is NCT00434148.

Acromegaly. A randomized, double-blind human trial at 84 sites in 27 countries enrolled 358 patients with acromegaly who had not had medical therapy. It compared pasireotide LAR with octreotide LAR. The primary end point was biochemical control at month 12: GH below a set threshold plus normal IGF-1. That target was met by 31.3% with pasireotide and 19.2% with octreotide (P = .007). Hyperglycemia-related adverse events occurred in 57.3% versus 21.7% (Colao et al., 2014). A matching Novartis registry record is NCT00600886.

What side effects does the label list?

Neither label has a boxed warning. The Signifor label lists the most common reactions, seen in at least 20% of patients. In its pooled Cushing’s disease data from 162 patients, rates included:

  • diarrhea: 58%;
  • nausea: 52%;
  • hyperglycemia: 40%;
  • gallstones (cholelithiasis): 30%; and
  • diabetes mellitus: 18%.

Headache, abdominal pain and fatigue are also on the most common list. The warnings cover low cortisol (hypocortisolism), hyperglycemia and diabetes, slow heart rate and QT prolongation, and raised liver tests. They also cover gallstones and their complications, loss of other pituitary hormones, and fatty stools from poor fat absorption. The Signifor LAR label names diarrhea, gallstones, hyperglycemia and diabetes as reactions seen in at least 20% of patients.

What is pasireotide’s regulatory status, and how is it used in research?

Pasireotide is a prescription drug in the United States, regulated under NDAs. Novartis sponsored the pivotal trials; Drugs@FDA now lists Recordati Rare as the company for both products. DailyMed lists two labels: Signifor and Signifor LAR, both from Recordati Rare Diseases (DailyMed, 2026). The research summarized here is clinical: human trials in Cushing’s disease and acromegaly. The receptor-binding figures come from laboratory tests.

Frequently asked questions about pasireotide

Is pasireotide a peptide?

Yes. The label calls it a cyclohexapeptide: six amino acids joined in a ring.

When was pasireotide approved?

Drugs@FDA lists the original approval of Signifor on December 14, 2012.

How is pasireotide different from octreotide?

Both are somatostatin analogs. In the head-to-head acromegaly trial, pasireotide reached the control target more often, but hyperglycemia events were also more common.

Why does pasireotide raise blood sugar?

The label lists hyperglycemia and diabetes as a warning. Hyperglycemia was reported in 40% of patients in the pooled Cushing’s disease data.

Does pasireotide have a boxed warning?

No. Its warnings include low cortisol, hyperglycemia, heart rhythm effects, liver test rises and gallstones.

What to know now

  • Structure: cyclic hexapeptide somatostatin analog; C58H66N10O9; 1,047.2 g/mol.
  • Approval: Signifor, December 14, 2012; Signifor LAR, December 15, 2014; prescription only.
  • Mechanism: binds somatostatin receptors, tightest at subtype 5; lowers ACTH and GH secretion.
  • Evidence: 14.6% and 26.3% cortisol normalization in Cushing’s disease; 31.3% vs 19.2% control in acromegaly.
  • Safety: no boxed warning; hyperglycemia, diarrhea, nausea and gallstones are common.

What we’re watching

Further revisions to the Signifor and Signifor LAR labels on DailyMed, both last revised in July 2024. Related guides: octreotide, pegvisomant and corticotropin.

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Recordati Rare Diseases 2024, SIGNIFOR (pasireotide) prescribing information; Recordati Rare Diseases 2024, SIGNIFOR LAR (pasireotide) prescribing information; U.S. Food and Drug Administration. Drugs@FDA: NDA 200677 (SIGNIFOR) . Retrieved November 17, Drugs@FDA: NDA 200677 (SIGNIFOR); U.S. Food and Drug Administration. Drugs@FDA: NDA 203255 (SIGNIFOR LAR KIT) . Retrieved November 17, Drugs@FDA: NDA 203255 (SIGNIFOR LAR KIT); National Center for Biotechnology Information 2026, PubChem compound summary for CID 9941444, pasireotide; Colao 2012, The New England Journal of Medicine, 366; Novartis Pharmaceuticals 2007; Colao 2014, The Journal of Clinical Endocrinology & Metabolism, 99; Novartis Pharmaceuticals 2008; U.S. National Library of Medicine 2026, DailyMed SPL listing: pasireotide. All 10 citations

Back to the research library

References

  1. Recordati Rare Diseases, Inc. (2024). SIGNIFOR (pasireotide) prescribing information (revised 7/2024). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e053-2995a90a5d74
  2. Recordati Rare Diseases, Inc. (2024). SIGNIFOR LAR (pasireotide) prescribing information (revised 7/2024). DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0aad470-3f38-af97-e053-2995a90a383a
  3. U.S. Food and Drug Administration. Drugs@FDA: NDA 200677 (SIGNIFOR). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200677
  4. U.S. Food and Drug Administration. Drugs@FDA: NDA 203255 (SIGNIFOR LAR KIT). Retrieved November 17, 2026, from https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203255
  5. National Center for Biotechnology Information. (2026). PubChem compound summary for CID 9941444, pasireotide. Retrieved November 17, 2026, from https://pubchem.ncbi.nlm.nih.gov/compound/9941444
  6. Colao, A., et al. (2012). A 12-month phase 3 study of pasireotide in Cushing’s disease. The New England Journal of Medicine, 366(10), 914-924. https://doi.org/10.1056/NEJMoa1105743
  7. Novartis Pharmaceuticals. (2007). Safety and efficacy of different dose levels of pasireotide in patients with de novo, persistent or recurrent Cushing’s disease (ClinicalTrials.gov ID NCT00434148). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00434148
  8. Colao, A., et al. (2014). Pasireotide versus octreotide in acromegaly: A head-to-head superiority study. The Journal of Clinical Endocrinology & Metabolism, 99(3), 791-799. https://doi.org/10.1210/jc.2013-2480
  9. Novartis Pharmaceuticals. (2008). Safety and efficacy of pasireotide long acting release (LAR) vs. octreotide LAR in patients with active acromegaly (ClinicalTrials.gov ID NCT00600886). Retrieved November 17, 2026, from https://clinicaltrials.gov/study/NCT00600886
  10. U.S. National Library of Medicine. (2026). DailyMed SPL listing: pasireotide. Retrieved November 17, 2026, from https://dailymed.nlm.nih.gov/dailymed/services/v2/spls.json?drug_name=pasireotide